home > investor relations

Highlights

Interim Results to 30 June 2009

Revenues up 9% to £2.45 million (H1 2008: £2.25 million)
Net profit up to £157,000 (H1 2008: profit £56,000)
Cash and cash equivalents at 30 June £1.72 million (H1 2008: £276,000)
Fully diluted EPS increased to 0.09p (H1 2008: 0.04p)

Commenting on the results, Steve Harris, Chairman of Cyprotex PLC, said:

"With the new management changes now in place, the Company has performed well in the first half of 2009, consolidating revenue the gains and profitability of 2008. In the face of a challenging market for the CRO industry, our investments in additional products and services are beginning to bear fruit with the generation of significant revenues and new customers and we will continue to drive this momentum forward into 2010."

Download Interim results to 30 June 2009


March 18, 2010 End of Offer Period
March 17, 2010 Final Results
March 16, 2010 Rule 8.3 - Cyprotex PLC

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100